☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
fusion pharmaceuticals
Fusion Pharmaceuticals Doses First Patient with FPI-2265 in P-II Study for Metastatic Castration-Resistant Prostate Cancer
May 10, 2024
PharmaShots Weekly Snapshots (May 03 - 07, 2021)
May 7, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.
